Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Pfizer's Xeljanz Pushed By New Tailwind From Approval In Ulcerative Colitis

30 May 2018

• By Jessica Merrill

Airliner in flight

Related Content

New Agents To Invade UC Market As Biosimilars Put Pressure On Stalwarts

07 Sep 2017

Xeljanz's UC Indication On Track With Higher Doses After Unanimous Advisory Committee Votes

09 Mar 2018

Lilly May Need To Reassess Baricitinib Market After FDA Advisory Committee

24 Apr 2018

AbbVie's Upadacitinib Safety Appears Improved In Largest, Longest RA Study

10 Apr 2018

Pfizer's Xeljanz: The Slow Road To Blockbuster Status

04 May 2017

Related Companies

Pfizer Inc.

Takeda Pharmaceutical Co. Ltd.

Eli Lilly and Company

Allergan plc

AbbVie Inc.

Additional Topics

Approvals Business Strategies Market Intelligence Commercial Gastrointestinal BioPharmaceutical

More from New Products

More from Scrip

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.